Tocilizumab Exerts Anti-Tumor Effects on Colorectal Carcinoma Cell Xenografts Corresponding to Expression Levels of Interleukin-6 Receptor
The use of tocilizumab against the interleukin-6 receptor (IL-6R) has been demonstrated as inhibiting the progression of diverse cancers in vitro and in vivo. Nonetheless, evidence regarding the anti-tumor effects of tocilizumab on human colorectal carcinoma (CRC) corresponding to IL-6R expression levels remains scarce. To investigate the influence of IL-6R expression, SW480 and HT-29 cells inoculated subcutaneously into NU/NU mice were used as human CRC xenograft models with anti-IL-6R antibody (tocilizumab) therapy. The IL-6R expression levels, histology of CRC growth/invasiveness, and tumor growth-related signaling pathway were estimated by H&E and immunohistochemical staining. SW480 tumor cells with higher IL-6R expression levels showed better responsiveness in tocilizumab therapy than in the treated HT-29 group. Likewise, therapeutic effects of tocilizumab on the proliferative ability with mitotic index and Ki-67 expressions, invasiveness with MMP-9 proteinase expressions, and ERK 1/2 and STAT3 signaling transduction in the SW480 treatment group were superior to the HT-29 treatment group. In light of our results, IL-6R is the key indicator for the efficacy of tocilizumab treatment in CRC xenografts. From the perspective of precision medicine, tumor response to anti-IL-6R antibody therapy could be predicted on the basis of IL-6R expression levels. In this manner, tocilizumab may serve as a targeted and promising anti-CRC therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Pharmaceuticals - 17(2024), 1, p 127 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuan-Chiang Chung [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Colorectal carcinoma |
|---|
| doi: |
10.3390/ph17010127 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ096310022 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ096310022 | ||
| 003 | DE-627 | ||
| 005 | 20240413150141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ph17010127 |2 doi | |
| 035 | |a (DE-627)DOAJ096310022 | ||
| 035 | |a (DE-599)DOAJad4a2e04bfc648719f0de76f496a4a45 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RS1-441 | |
| 100 | 0 | |a Yuan-Chiang Chung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab Exerts Anti-Tumor Effects on Colorectal Carcinoma Cell Xenografts Corresponding to Expression Levels of Interleukin-6 Receptor |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The use of tocilizumab against the interleukin-6 receptor (IL-6R) has been demonstrated as inhibiting the progression of diverse cancers in vitro and in vivo. Nonetheless, evidence regarding the anti-tumor effects of tocilizumab on human colorectal carcinoma (CRC) corresponding to IL-6R expression levels remains scarce. To investigate the influence of IL-6R expression, SW480 and HT-29 cells inoculated subcutaneously into NU/NU mice were used as human CRC xenograft models with anti-IL-6R antibody (tocilizumab) therapy. The IL-6R expression levels, histology of CRC growth/invasiveness, and tumor growth-related signaling pathway were estimated by H&E and immunohistochemical staining. SW480 tumor cells with higher IL-6R expression levels showed better responsiveness in tocilizumab therapy than in the treated HT-29 group. Likewise, therapeutic effects of tocilizumab on the proliferative ability with mitotic index and Ki-67 expressions, invasiveness with MMP-9 proteinase expressions, and ERK 1/2 and STAT3 signaling transduction in the SW480 treatment group were superior to the HT-29 treatment group. In light of our results, IL-6R is the key indicator for the efficacy of tocilizumab treatment in CRC xenografts. From the perspective of precision medicine, tumor response to anti-IL-6R antibody therapy could be predicted on the basis of IL-6R expression levels. In this manner, tocilizumab may serve as a targeted and promising anti-CRC therapy. | ||
| 650 | 4 | |a interleukin-6 receptor | |
| 650 | 4 | |a colorectal carcinoma | |
| 650 | 4 | |a xenograft | |
| 650 | 4 | |a tocilizumab | |
| 650 | 4 | |a Ki-67 | |
| 650 | 4 | |a ERK 1/2 | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 700 | 0 | |a Szu-Jung Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Chiu-Chen Huang |e verfasserin |4 aut | |
| 700 | 0 | |a Wei-Chun Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Ming-Tsung Lai |e verfasserin |4 aut | |
| 700 | 0 | |a Ting-Yu Kao |e verfasserin |4 aut | |
| 700 | 0 | |a Wei-Shun Yang |e verfasserin |4 aut | |
| 700 | 0 | |a Chien-Hui Yang |e verfasserin |4 aut | |
| 700 | 0 | |a Chih-Ping Hsu |e verfasserin |4 aut | |
| 700 | 0 | |a Jia-Feng Chang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Pharmaceuticals |d MDPI AG, 2005 |g 17(2024), 1, p 127 |w (DE-627)DOAJ000006718 |x 14248247 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g number:1, p 127 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ph17010127 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ad4a2e04bfc648719f0de76f496a4a45 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1424-8247/17/1/127 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1424-8247 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |e 1, p 127 | ||